Cargando…

Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results

AIMS: This paper presents the treatment outcomes for patients intiated on biphasic insulin aspart 30 (BIAsp 30) treatment: BIAsp 30-only, BIAsp 30 + sulphonylureas (SU), BIAsp 30 + biguanides (BI), BIAsp 30 + SU + BI, BIAsp 30 + alpha-glucosidase inhibitors (GI), and BIAsp 30 + BI + thiazolidinedion...

Descripción completa

Detalles Bibliográficos
Autores principales: Güler, Serdar, Sharma, Surendra Kumar, Almustafa, Majeed, Kim, Chong Hwa, Azar, Sami, Danciulescu, Rucsandra, Shestakova, Marina, Khutsoane, Duma, Bech, Ole Molskov
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Inc 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721962/
https://www.ncbi.nlm.nih.gov/pubmed/19684847
http://dx.doi.org/10.1111/j.1753-5174.2008.00015.x
_version_ 1782170263526309888
author Güler, Serdar
Sharma, Surendra Kumar
Almustafa, Majeed
Kim, Chong Hwa
Azar, Sami
Danciulescu, Rucsandra
Shestakova, Marina
Khutsoane, Duma
Bech, Ole Molskov
author_facet Güler, Serdar
Sharma, Surendra Kumar
Almustafa, Majeed
Kim, Chong Hwa
Azar, Sami
Danciulescu, Rucsandra
Shestakova, Marina
Khutsoane, Duma
Bech, Ole Molskov
author_sort Güler, Serdar
collection PubMed
description AIMS: This paper presents the treatment outcomes for patients intiated on biphasic insulin aspart 30 (BIAsp 30) treatment: BIAsp 30-only, BIAsp 30 + sulphonylureas (SU), BIAsp 30 + biguanides (BI), BIAsp 30 + SU + BI, BIAsp 30 + alpha-glucosidase inhibitors (GI), and BIAsp 30 + BI + thiazolidinediones (TZD) after failing oral antidiabetic drugs (OADs) treatment. METHODS: This was a multi-national, multi-centre, six-month, prospective, open-labelled, uncontrolled, clinical experience evaluation study, with the exception of a three-month study in one country (China) (“all exclude China” and “China”). Initiation and discontinuation of BIAsp 30 treatment were entirely at the discretion of the attending physicians. RESULTS: Mean HbA(1c), FPG and PPPG were significantly reduced from baseline at three and six months in all groups (P < 0.001). In “all exclude China”, reductions in mean HbA(1c), FPG and PPPG at six months were as follows: BIAsp 30-only group (−2.12 ± 1.76% points; −4.82 ± 3.86 mmol/L; −6.89 ± 4.74 mmol/L), BIAsp 30 + BI group (−2.24 ± 1.77% points; −4.48 ± 3.68 mmol/L; −6.66 ± 4.55 mmol/L), BIAsp 30 + SU group (−1.95 ± 1.59% points; −3.98 ± 3.19 mmol/L; −6.25 ± 4.45 mmol/L) and BIAsp 30 + SU + BI group (−1.78 ± 1.20% points; −3.57 ± 2.78 mmol/L; −5.89 ± 3.98 mmol/L). The only serious adverse drug reaction was reported by the BIAsp 30-only group. In the “China” group, reductions in mean HbA(1c), FPG and PPPG at three months were: BIAsp 30-only group (−2.16 ± 1.52% points; −3.34 ± 2.49 mmol/L; −6.29 ± 3.92 mmol/L), BIAsp 30 + BI group (−2.44 ± 1.52% points; −4.01 ± 2.50 mmol/L; −7.10 ± 3.96 mmol/L), BIAsp 30 + GI group (−2.33 ± 1.41% points; −4.34 ± 2.52 mmol/L; −7.97 ± 3.99 mmol/L) and BIAsp 30 + BI + TZD group (−1.21 ± 1.60% points; −3.50 ± 2.29 mmol/L; −5.97 ± 3.39 mmol/L). No serious ADR were reported in China. The most frequent hypoglycaemic episodes were diurnal and minor in nature. CONCLUSIONS: BIAsp 30 treatment in a clinical setting improved glycaemic control in type 2 diabetes patients failing OADs.
format Text
id pubmed-2721962
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Blackwell Publishing Inc
record_format MEDLINE/PubMed
spelling pubmed-27219622009-08-14 Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results Güler, Serdar Sharma, Surendra Kumar Almustafa, Majeed Kim, Chong Hwa Azar, Sami Danciulescu, Rucsandra Shestakova, Marina Khutsoane, Duma Bech, Ole Molskov Arch Drug Inf Original Articles AIMS: This paper presents the treatment outcomes for patients intiated on biphasic insulin aspart 30 (BIAsp 30) treatment: BIAsp 30-only, BIAsp 30 + sulphonylureas (SU), BIAsp 30 + biguanides (BI), BIAsp 30 + SU + BI, BIAsp 30 + alpha-glucosidase inhibitors (GI), and BIAsp 30 + BI + thiazolidinediones (TZD) after failing oral antidiabetic drugs (OADs) treatment. METHODS: This was a multi-national, multi-centre, six-month, prospective, open-labelled, uncontrolled, clinical experience evaluation study, with the exception of a three-month study in one country (China) (“all exclude China” and “China”). Initiation and discontinuation of BIAsp 30 treatment were entirely at the discretion of the attending physicians. RESULTS: Mean HbA(1c), FPG and PPPG were significantly reduced from baseline at three and six months in all groups (P < 0.001). In “all exclude China”, reductions in mean HbA(1c), FPG and PPPG at six months were as follows: BIAsp 30-only group (−2.12 ± 1.76% points; −4.82 ± 3.86 mmol/L; −6.89 ± 4.74 mmol/L), BIAsp 30 + BI group (−2.24 ± 1.77% points; −4.48 ± 3.68 mmol/L; −6.66 ± 4.55 mmol/L), BIAsp 30 + SU group (−1.95 ± 1.59% points; −3.98 ± 3.19 mmol/L; −6.25 ± 4.45 mmol/L) and BIAsp 30 + SU + BI group (−1.78 ± 1.20% points; −3.57 ± 2.78 mmol/L; −5.89 ± 3.98 mmol/L). The only serious adverse drug reaction was reported by the BIAsp 30-only group. In the “China” group, reductions in mean HbA(1c), FPG and PPPG at three months were: BIAsp 30-only group (−2.16 ± 1.52% points; −3.34 ± 2.49 mmol/L; −6.29 ± 3.92 mmol/L), BIAsp 30 + BI group (−2.44 ± 1.52% points; −4.01 ± 2.50 mmol/L; −7.10 ± 3.96 mmol/L), BIAsp 30 + GI group (−2.33 ± 1.41% points; −4.34 ± 2.52 mmol/L; −7.97 ± 3.99 mmol/L) and BIAsp 30 + BI + TZD group (−1.21 ± 1.60% points; −3.50 ± 2.29 mmol/L; −5.97 ± 3.39 mmol/L). No serious ADR were reported in China. The most frequent hypoglycaemic episodes were diurnal and minor in nature. CONCLUSIONS: BIAsp 30 treatment in a clinical setting improved glycaemic control in type 2 diabetes patients failing OADs. Blackwell Publishing Inc 2009-06 /pmc/articles/PMC2721962/ /pubmed/19684847 http://dx.doi.org/10.1111/j.1753-5174.2008.00015.x Text en © 2009, Archives of Drug Information http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Original Articles
Güler, Serdar
Sharma, Surendra Kumar
Almustafa, Majeed
Kim, Chong Hwa
Azar, Sami
Danciulescu, Rucsandra
Shestakova, Marina
Khutsoane, Duma
Bech, Ole Molskov
Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results
title Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results
title_full Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results
title_fullStr Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results
title_full_unstemmed Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results
title_short Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results
title_sort improved glycaemic control with biphasic insulin aspart 30 in type 2 diabetes patients failing oral antidiabetic drugs: present study results
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721962/
https://www.ncbi.nlm.nih.gov/pubmed/19684847
http://dx.doi.org/10.1111/j.1753-5174.2008.00015.x
work_keys_str_mv AT gulerserdar improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults
AT sharmasurendrakumar improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults
AT almustafamajeed improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults
AT kimchonghwa improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults
AT azarsami improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults
AT danciulescurucsandra improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults
AT shestakovamarina improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults
AT khutsoaneduma improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults
AT becholemolskov improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults